Gastrointestinal Diagnostics Market Size & Share 2024 - 2032

Gastrointestinal Diagnostics Market Size

Gastrointestinal Diagnostics Market size was valued at USD 4.8 billion in 2023 and is expected to exhibit growth at a CAGR of 4.6% from 2024 and 2032. High market growth can be attributed to the ongoing advancements in diagnostic technologies, increasing prevalence of GI disorders, rising adoption of non-invasive diagnostic techniques, and growing healthcare expenditure, among other contributing factors.

Moreover, the rising incidence of GI disorders such as colorectal cancer, inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and others is a significant driver for GI diagnostics. For instance, as per the data published in Springer Nature, in 2023, inflammatory bowel disease (IBD) affects over 0.3% of the global population. Similarly, according to the NCBI, the national incidence of IBD was projected to be 29.9 per 100,000 in 2023. As the global population ages and lifestyles change, the prevalence of these conditions increases, necessitating more diagnostic procedures.
 

Furthermore, advances in diagnostic technologies have greatly improved the accuracy, sensitivity, and speed of GI diagnostic tests. Innovations such as endoscopic ultrasound (EUS), capsule endoscopy, virtual colonoscopy, and molecular diagnostics have enhanced clinicians' ability to detect and diagnose GI conditions at earlier stages, leading to better patient outcomes.
 

Gastrointestinal diagnostics refers to the array of medical procedures, tests, and techniques used to diagnose and evaluate disorders and diseases affecting the gastrointestinal (GI) tract, which includes the stomach, intestines, esophagus, liver, gallbladder, and pancreas.
 

Gastrointestinal Diagnostics Market Trends

The market is experiencing several notable trends that are shaping its growth and development. Factors such as continuous innovations in diagnostic technologies, growing demand for non-invasive diagnostic approaches, rising focus on early detection and screening programs, and surging demand for integrated artificial intelligence in healthcare and machine learning, among other factors are propelling the industry growth.
 

• Further, there is a growing demand for non-invasive diagnostic approaches in the GI diagnostics market. Non-invasive tests, such as stool-based tests for colorectal cancer diagnostics, breath tests for Helicobacter pylori infection, and serum biomarker assays for inflammatory bowel disease (IBD), offer convenience, ease of use, and reduced patient discomfort. As a result, there is an increasing focus on the development of non-invasive diagnostic technologies and biomarkers for various GI disorders, driving market growth in this segment.
   
• Moreover, point-of-care testing for GI conditions is expanding, driven by the need for rapid and convenient diagnostic solutions. POCT devices for detecting gastrointestinal infections, inflammation, and occult blood are becoming more prevalent in primary care settings, emergency departments, and outpatient clinics, enabling timely decision-making and treatment initiation, thereby aforementioned factors are expected to drive the market.
   

Gastrointestinal Diagnostics Market Analysis

Based on test type, the gastrointestinal diagnostics market is categorized into endoscopy, blood test, immunoglobulin A test, H. pylori test, calprotectin test, and other test types. The endoscopy generated the highest revenue of USD 1.7 billion in 2023.
 

• Endoscopy provides direct visualization of the gastrointestinal (GI) tract, allowing for accurate and precise diagnosis of various GI conditions such as ulcers, polyps, inflammation, and tumors. Compared to imaging techniques alone, endoscopy offers superior diagnostic capabilities, enabling clinicians to identify abnormalities with high sensitivity and specificity.
   
• Additionally, endoscopic procedures like colonoscopy and upper gastrointestinal endoscopy are essential for screening and early detection of GI cancers, including colorectal cancer, esophageal cancer, gastric cancer, and pancreatic cancer. Early detection through endoscopy allows for timely intervention and improved patient outcomes, driving the demand for endoscopic services in screening programs, thus leading to the segmental growth.

Learn more about the key segments shaping this market

Download Free PDF

Based on technology, the gastrointestinal diagnostics market is classified into culture and sensitivity testing, ELISA, PCR, imaging technologies, rapid diagnostic tests, and other technologies. The culture and sensitivity testing segment dominated the market in 2023 with a market share of 33.6%.
 

• Gastrointestinal infections are common worldwide, caused by various pathogens such as bacteria, viruses, parasites, and fungi. Factors such as poor sanitation, contaminated food and water, antibiotic resistance, and global travel contribute to the increasing incidence of GI infections. As a result, there is a growing need for accurate and timely identification of causative agents through culture and sensitivity testing to guide appropriate treatment.
   
• Furthermore, effective treatment of GI infections relies on selecting the most appropriate antimicrobial agents based on the susceptibility profile of the causative pathogens. Culture and sensitivity testing provide valuable information about the susceptibility patterns of bacterial isolates to various antibiotics, allowing healthcare providers to tailor treatment regimens to individual patients and optimize therapeutic outcomes. This is anticipated to boost the segmental growth in the market.
   

Based on application, the gastrointestinal diagnostics market is classified into infection, gastrointestinal cancer, inflammatory bowel disease, gastroesophageal reflux disease (GERD), and other applications. The infection segment dominated the market and is expected to grow at a pace of 4.8% CAGR between 2024 – 2032.
 

• Antibiotic resistance is a growing problem in the management of GI infections, particularly those caused by bacterial pathogens. Overuse and misuse of antibiotics contribute to the emergence of resistant strains, complicating treatment and increasing the risk of treatment failure. Diagnostic tests that include antimicrobial susceptibility testing (AST) help guide appropriate antibiotic therapy by identifying effective treatment options and minimizing the development of antibiotic resistance.
   
• Moreover, advances in diagnostic technologies, including molecular diagnostics, next-generation sequencing (NGS), multiplex PCR assays, and rapid antigen detection tests, have revolutionized the detection and characterization of GI pathogens. These technologies offer improved sensitivity, specificity, and turnaround time compared to traditional methods, enabling more efficient and accurate diagnosis of GI infections.
   

Based on end-use, the gastrointestinal diagnostics market is segmented into hospitals, diagnostic laboratories, and other end-users. The hospitals segment dominated the market in 2023 and is anticipated to reach USD 4.1 billion by the end of forecast period.
 

• Hospitals often strive to establish themselves as centers of clinical excellence, offering specialized services in various medical specialties, including gastroenterology and digestive health. Hospitals with specialized GI departments attract patients seeking expert diagnosis and treatment for complex GI conditions, driving the demand for advanced GI diagnostic procedures.
   
• Furthermore, many hospitals integrate diagnostic services within their facilities, offering a one-stop solution for patients' diagnostic needs. By providing a wide range of GI diagnostic tests and procedures in-house, hospitals enhance patient convenience, streamline care delivery, and foster continuity of care, leading to improved patient satisfaction and loyalty.

North America gastrointestinal diagnostics market accounted for USD 1.9 billion market revenue in 2023 and is anticipated to grow at CAGR of 4.4% between 2024 – 2032 period.
 

• North America faces a significant burden of gastrointestinal diseases, including colorectal cancer, inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and infectious gastrointestinal illnesses. Factors such as aging populations, sedentary lifestyles, unhealthy dietary habits, and genetic predispositions contribute to the prevalence of GI disorders, driving the demand for diagnostic services.
   
• Furthermore, both the U.S. and Canada have established national screening programs for colorectal cancer, promoting routine screening for individuals over a certain age (typically 50 years and older). These screening initiatives, which utilize various diagnostic modalities such as fecal occult blood tests (FOBT), colonoscopy, and stool DNA testing, drive the demand for GI diagnostic services in the region.
   

The U.S. held a dominant position in the gastrointestinal diagnostics market, with a revenue of USD 1.7 billion in 2023.
 

• The U.S. boasts of advanced healthcare infrastructure, including hospitals, diagnostic laboratories, outpatient clinics, and ambulatory surgical centers equipped with state-of-the-art diagnostic technologies and facilities. The availability of advanced endoscopy suites, imaging modalities, and molecular diagnostic platforms supports the delivery of comprehensive GI diagnostic services nationwide.
   
• Moreover, the majority of Americans have health insurance coverage, either through private health insurance plans, employer-sponsored insurance, or government programs such as Medicare and Medicaid. Health insurance coverage facilitates access to GI diagnostic services, ensuring that patients can undergo screening, diagnostic testing, and treatment without facing significant financial barriers.
   

Germany gastrointestinal diagnostics market is projected to grow remarkably in the coming years.
 

• Germany has one of the largest healthcare systems in Europe, characterized by high healthcare expenditure and a robust infrastructure. The country's universal health insurance system ensures access to healthcare services for its population, including diagnostic tests and procedures for GI disorders.
   
• Additionally, the country has a well-established regulatory framework for medical devices and diagnostics, ensuring the safety, quality, and efficacy of products entering the market. Compliance with regulatory requirements, including CE marking for diagnostic devices, is essential for market access and reimbursement in Germany's healthcare system.
   

Japan holds a dominant position in the Asia Pacific gastrointestinal diagnostics market.
 

• Japan is known for its technological innovations and advancements in medical devices and diagnostics. The country's expertise in endoscopic imaging, therapeutic endoscopy, and minimally invasive procedures drives innovation in GI diagnostics.
   
• Japanese companies develop and commercialize cutting-edge technologies, such as high-definition endoscopes, capsule endoscopy systems, and AI-enabled diagnostic tools, which enhance the accuracy and efficiency of GI diagnostics.
   

Gastrointestinal Diagnostics Market Share

The market is experiencing significant growth due to rising global prevalence of GI disorders like colorectal cancer and IBD, fuelled by factors such as aging populations and lifestyle changes. Key players, including diagnostic labs, healthcare providers, and medical device manufacturers, drive innovation with technologies like molecular diagnostics and AI-enabled tools, expanding diagnostic capabilities. Initiatives in preventive medicine and personalized healthcare are reshaping the landscape, emphasizing early detection and tailored treatment approaches. As demand for accurate GI diagnostics continues to escalate, market expansion, collaboration, and investment in advanced solutions are key strategies for industry players.
 

Gastrointestinal Diagnostics Market Companies

Prominent players operating in the gastrointestinal diagnostics industry include:

• Abbott Laboratories
• Beckman Coulter, Inc.
• Becton, Dickinson and Company
• bioMérieux
• Bio-Rad Laboratories, Inc.
• DiaSorin S.p.A
• EKF Diagnostics Holdings plc
• F. Hoffmann-La Roche Ltd
• Fujifilm Holdings Corporation
• Meridian Bioscience
• QIAGEN N.V.
• R-Biopharm AG
• Siemens Healthineers AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
   

Gastrointestinal Diagnostics Industry News:

• In February 2024, ELITechGroup announced the launch of the GI Parasitic PLUS ELITe MGB Kit, the second addition to its gastrointestinal infection testing range. Manufactured specifically for identifying gastrointestinal parasite diseases, it is intended to provide a holistic approach for controlling life-threatening gastrointestinal infections, indicating a key milestone in ELITechGroup's goal to provide cutting-edge diagnostic solutions.
   
• In August 2023, QIAGEN announced that its therascreen PDGFRA RGQ PCR kit has been approved by the US Food and Drug Administration.  This companion diagnostic is intended to help clinicians identify patients with gastrointestinal stromal tumors (GIST) who may be eligible for treatment with AYVAKIT (avapritinib), which is approved in the U.S. to treat adults with incurable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
   

The gastrointestinal diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Endoscopy
• Blood test
• Immunoglobulin A test
• H. pylori test
• Calprotectin test
• Other test types

Market, By Technology

• Culture and sensitivity testing
• ELISA
• PCR
• Imaging technologies
• Rapid diagnostic tests
• Other technologies

Market, By Application

• Infection
• Gastrointestinal cancer
• Inflammatory bowel disease
• Gastroesophageal reflux disease (GERD)
• Other applications

Market, By End-use

• Hospitals
• Diagnostic laboratories
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa